A61K 49/0002
General or multifunctional contrast agents
Official title: {General or multifunctional contrast agents, e.g. chelated agents}
A61K49/0002 (General or multifunctional contrast agents) appears on 867 US grants and 1,452 published applications in this corpus.
Search patents in A61K- Granted patents
- 867
- Published applications
- 1,452
- Assignees
- 717
- Inventors
- 2,982
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 5 | 0 |
| 1994 | 8 | 0 |
| 1995 | 14 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 18 | 0 |
| 1999 | 12 | 0 |
| 2000 | 10 | 0 |
| 2001 | 11 | 4 |
| 2002 | 8 | 34 |
| 2003 | 24 | 53 |
| 2004 | 16 | 51 |
| 2005 | 16 | 58 |
| 2006 | 24 | 57 |
| 2007 | 20 | 56 |
| 2008 | 19 | 54 |
| 2009 | 17 | 59 |
| 2010 | 27 | 69 |
| 2011 | 21 | 83 |
| 2012 | 39 | 76 |
| 2013 | 59 | 76 |
| 2014 | 51 | 74 |
| 2015 | 47 | 76 |
| 2016 | 47 | 72 |
| 2017 | 49 | 53 |
| 2018 | 61 | 62 |
| 2019 | 37 | 62 |
| 2020 | 34 | 65 |
| 2021 | 31 | 45 |
| 2022 | 35 | 36 |
| 2023 | 21 | 48 |
| 2024 | 21 | 55 |
| 2025 | 22 | 36 |
| 2026 | 15 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Peptide libraries with non-canonical amino acids6 Oct 2026US 12,753,205 B2Regeneron Pharmaceuticals, Inc.
- Liver-targeted fluorescence/photoacoustic dual-modal probe for early detecting drug-induced hepatic inflammation and autoimmune hepatitis22 Sep 2026US 12,741,037 B2Beijing University of Technology
- Thrombus imaging aptamers and methods of using same4 Aug 2026US 12,697,401 B2Duke University
- Antibodies to galectin-3 and methods of use thereof16 Jun 2026US 12,655,221 B2Memorial Sloan Kettering Cancer Center
- Macropinocytosis selective monobody-drug conjugates2 Jun 2026US 12,642,859 B2New York University
- Antibody targeting dll3 and use of antibody8 Oct 2026US 2026/0308240 A1Neukio Biotherapeutics (Shanghai) Co., Ltd.
- Polypeptide adjuvants and uses thereof24 Sep 2026US 2026/0284209 A1Board of Regents, The University of Texas System
- Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide24 Sep 2026US 2026/0284218 A1Cdr-Life AG
- Fc containing polypeptides with altered glycosylation and reduced effector function17 Sep 2026US 2026/0274926 A1Genzyme Corporation
- Rage receptor-binding molecules, conjugates thereof and their uses to detect, prevent or treat lung diseases17 Sep 2026US 2026/0274944 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Particle immobilized coatings and uses thereof1,386US 8,679,454 B2SurModics, Inc. · 2014
- Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment581US 4,805,623 AVander Corporation · 1989
- Molecules with extended half-lives, compositions and uses thereof342US 7,083,784 B2MedImmune, LLC · 2006
- Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor289US 5,439,686 AVivorx Pharmaceuticals, Inc. · 1995
- Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors228US 6,261,537 B1Nycomed Imaging AS · 2001